DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

Although some important advances have been achieved in clinical and diagnosis in the past few years, the management of non-small cell lung cancer (NSCLC) is ultimately dissatisfactory due to the low overall cure and survival rates. Epidermal growth factor (EGFR) has been recognized as a carcinogenic...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Xiao-Ping Zhao, Xiao-Li Zheng, Min Huang, Ya-Jia Xie, Xiao-Wen Nie, Ali Adnan Nasim, Xiao-Jun Yao, Xing-Xing Fan
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2023-05-01
Saila:Heliyon
Gaiak:
EGFR mutation
NSCLC
Lung cancer
DMU-212
EGFR-AMPK pathway
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S2405844023030190

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023030190

Antzeko izenburuak